Novel GLP-1 receptor agonists for diabetes

Garber, Alan J

doi:10.1517/13543784.2012.638282

Cited by 69Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes Management and Research

Novel GLP-1 receptor agonists for diabetes

Garber, Alan J·2012·Expert Opinion on Investigational Drugs

DOI 10.1517/13543784.2012.638282

Open this paper in CoChat — free account

Abstract

INTRODUCTION: GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed. Indeed, liraglutide, a once-daily GLP-1 receptor agonist, was approved in 2010, and more recently, a once-weekly formulation of exenatide was approved in 2011. This review considers the mechanism of action of GLP-1 receptor agonists and considers the various agents in this class. AREAS COVERED: The importance of GLP-1 itself in glycemic control and the use of GLP-1 receptor agonists in T2DM are discussed. An overview of the clinical development of the five GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide and taspoglutide) since 2005 is provided and their mechanisms of action, efficacy in terms of glycemic control and weight loss, and tolerability are reviewed. EXPERT OPINION: GLP-1 receptor agonists result in clinically meaningful weight loss in addition to their beneficial effects on glucose homeostasis. These agents provide substantial clinical benefits for patients compared with sulfonylureas or DPP-4 inhibitors and will, therefore, become one of the major therapeutic choices for patients with T2DM.

Integrity signals

Registry

Crossref · 10.1517/13543784.2012.638282

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

GLP-1 receptor agonists may assist patients in reaching glycemic goals and controlling appetite, with possible reduction of uncontrollable hunger and bulimic symptoms.
“Adjunctive medication such as glucagon-like peptide 1 receptor agonists (86) may not only help individuals meet glycemic targets but also help regulate hunger and food intake, thus having the potential to reduce uncontrollable hunger and bulimic symptoms.”
From Psychosocial care for people with diabetes: a position statement of the American Diabetes Association (2016) · cites this paper as [86]

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1× · see citing works
“Indeed, patients considered to be at high risk of developing diabetes have been shown to significantly reduce their risk by undertaking lifestyle changes [91].”
Background
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377 · see citing works
Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works
Self-citation
Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942 · see citing works
Self-citation
Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · see citing works
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works
Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
WAJCHENBERG, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 716 · see citing works
Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 705 · see citing works
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works
Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654 · see citing works
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 611 · see citing works
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J. L., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 607 · see citing works
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · see citing works
Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · see citing works
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 484 · see citing works
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · see citing works
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447 · see citing works
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · see citing works
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works
Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s
Fox, C. S., Pencina, M. J., Meigs, J. B., Vasan, R. S., Levitzky, Y. S., & D’Agostino, R. B. (2006) · Circulation · doi:10.1161/circulationaha.106.613828 · Cited by 378 · see citing works
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373 · see citing works
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Buse, J. B., Drucker, D. J., Taylor, K., Kim, T., Walsh, B., Hu, H., Wilhelm, K., TRAUTMANN, M. E., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 357 · see citing works
Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets
Maedler, K., Carr, R. D., Bosco, D., Zuellig, R. A., Berney, T., & Donath, M. Y. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0699 · Cited by 337 · see citing works
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))
Zinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290 · see citing works
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244 · see citing works
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Barnett, A. H., Burger, J., Johns, D., Brodows, R. G., Kendall, D. M., Roberts, A., & TRAUTMANN, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.006 · Cited by 240 · see citing works
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J. E. B., Bush, M., Yang, F., Stewart, M. W., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237 · see citing works
Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2
Brubaker, P. L., & Anini, Y. (2003) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y03-107 · Cited by 220 · see citing works
Nutritional regulation of glucagon‐like peptide‐1 secretion
Tolhurst, G., Reimann, F. M., & Gribble, F. M. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164012 · Cited by 214 · see citing works
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Matthews, J. E., Stewart, M. W., Boever, E. H. D., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198 · see citing works
Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard
Chen, Y. E., & Drucker, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4108 · Cited by 167 · see citing works
Glucagon-like peptide-1, glucose homeostasis and diabetes
Holst, J. J., Deacon, C. F., Vilsbøll, T., Krarup, T., & Madsbad, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.01.003 · Cited by 160 · see citing works
Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 155 · see citing works
Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes
Knudsen, L. B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030630m · Cited by 154 · see citing works
GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.
Buteau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73398-6 · Cited by 152 · see citing works
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 152 · see citing works
The Safety of Incretin-Based Therapies—Review of the Scientific Evidence
Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 148 · see citing works
Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133 · see citing works
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
Madsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 128 · see citing works
Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes
Dupré, J., Behme, M. T., & McDonald, T. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032001 · Cited by 127 · see citing works
Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?
Grieve, D., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 121 · see citing works
DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide
Wysham, C., Bergenstal, R. M., Malloy, J. L., Yan, P., Walsh, B., Malone, J. K., & Taylor, K. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03301.x · Cited by 118 · see citing works
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
Nauck, M. A., Ratner, R. E., Kapitza, C., Berria, R., Boldrin, M. N., & Balena, R. (2009) · Diabetes Care · doi:10.2337/dc08-1961 · Cited by 117 · see citing works
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus
Montanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 117 · see citing works
Neural regulation of glucagon-like peptide-1 secretion in pigs
Hansen, L., Lampert, S., Mineo, H., & Holst, J. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00197.2004 · Cited by 107 · see citing works
Meal-Anticipatory Glucagon-Like Peptide-1 Secretion in Rats
Vahl, T. P., Drazen, D. L., Seeley, R. J., D’Alessio, D. A., & Woods, S. C. (2009) · Endocrinology · doi:10.1210/en.2009-1002 · Cited by 100 · see citing works
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 97 · see citing works
Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
Behme, M. T., Dupré, J., & McDonald, T. J. (2003) · BMC Endocrine Disorders · doi:10.1186/1472-6823-3-3 · Cited by 88 · see citing works
Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans
Pannacciulli, N., Bunt, J. C., Koška, J., Bogardus, C., & Krakoff, J. A. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.3.556 · Cited by 85 · see citing works
Patient‐reported outcomes following treatment with the human GLP‐1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
Bode, B. W., Testa, M. A., MAGWIRE, M. L., Hale, P. M., Hammer, M., Blonde, L., Garber, A. J., & on behalf of the LEAD‐3 Study Group (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01196.x · Cited by 76 · see citing works
Self-citation
Advances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors
Kennedy, L., & Davidson, J. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.05 · Cited by 75 · see citing works
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
Christensen, M., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · PubMed · Cited by 74 · see citing works
The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions
Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.001 · Cited by 71 · see citing works
Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., & Campbell, R. K. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m134 · Cited by 63 · see citing works
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
Mikhail, N. E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.845 · Cited by 62 · see citing works
Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
Onge, E. S., & Miller, S. A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481281 · Cited by 61 · see citing works
Exenatide and weight loss
Bradley, D. P., Kulstad, R., & Schoeller, D. A. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.008 · Cited by 59 · see citing works
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55 · see citing works
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Christensen, M., & Knop, F. K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0102-x · Cited by 46 · see citing works
Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
Seino, Y., Nakajima, H., Miyahara, H., Kurita, T., Bush, M., Yang, F., Stewart, M. W., & For the Albiglutide Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903372999 · Cited by 45 · see citing works
Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study1,2
Ratner, R. E., Nauck, M. A., Kapitza, C., Asnaghi, V., Boldrin, M. N., & Balena, R. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02990.x · Cited by 44 · see citing works
On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights.
Vaag, A. A. (1999) · PubMed · Cited by 41 · see citing works
The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38 · see citing works
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once‐weekly, human GLP‐1 analogue, after single‐dose administration in patients with Type 2 diabetes
Kapitza, C., Heise, T., BIRMAN, P., Jallet, K., Ramis, J., & Balena, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02854.x · Cited by 33 · see citing works
Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.
TOMKIN, G. H. (2009) · PubMed · Cited by 29 · see citing works
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
Penfornis, A., Borot, S., & Raccah, D. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73399-8 · Cited by 27 · see citing works
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Vilsbøll, T., Holst, J. J., & Knop, F. K. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.011 · Cited by 24 · see citing works
Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
Retterstøl, K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903164205 · Cited by 24 · see citing works
A Comparison of Agents Used to Manage Type 2 Diabetes Mellitus
Bell, D. S. H. (2004) · Treatments in Endocrinology · doi:10.2165/00024677-200403020-00001 · Cited by 19 · see citing works
Clinical Studies of Liraglutide, a Novel, Once‐Daily Human Glucagon‐Like Peptide‐1 Analog for Improved Management of Type 2 Diabetes Mellitus
Drab, S. R. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.43s · Cited by 18 · see citing works
The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.30 · Cited by 7 · see citing works

Flagged first, then by citations

Sorted by citations

Psychosocial care for people with diabetes: a position statement of the American Diabetes Association
Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2016) · Diabetes Care · doi:10.2337/dc16-2053 · Cited by 1,072 · see citing works
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · see citing works
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:<i>Standards of Medical Care in Diabetes—2022</i>
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s005 · Cited by 445 · see citing works
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191 · see citing works
Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes
Lu, N., Sun, H., Yu, J., Wang, X., Liu, D., Zhao, L., Sun, L., Zhao, H., Tao, B., & Liu, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132744 · Cited by 108 · see citing works
Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of <scp>G</scp>et<scp>G</scp>oal‐<scp>S</scp>
Onishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12275 · Cited by 13 · see citing works

Use of N-ethylmaleimide to directly determine the proportion of β-adrenergic receptors exhibiting high affinity for agonists on human mononuclear leukocyte membranes
Rigby, J. W., & Wood, A. J. J. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90428-0 · Cited by 1 · see citing works
Stressin1-A, a Potent Corticotropin Releasing Factor Receptor 1 (CRF1)-Selective Peptide Agonist
Rivier, J., Gulyás, J., Kunitake, K. S., DiGruccio, M. R., Cantle, J. P., Perrin, M. H., Donaldson, C., Vaughan, J. M., Million, M., Gourcerol, G., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0613875 · Cited by 42 · see citing works
Glucagon-like peptide-1 (GCG; GLP-1); GLP-1 receptor (GLP1R; GLP-1R)
(2009) · Science-Business eXchange · doi:10.1038/scibx.2009.111 · Cited by 1 · see citing works
Dual Receptor Agonist for Type 2 Diabetes
Slomski, A. J. (2018) · JAMA · doi:10.1001/jama.2018.20160 · Cited by 1 · see citing works
Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 23 · see citing works

Authors: Garber, A. J.
Affiliations: Baylor College of Medicine (US)
Corresponding author: Garber, Alan J
Venue: Expert Opinion on Investigational Drugs
Publisher: Informa Healthcare
Published: 2011-11-24
Volume: 21
Issue: 1
Pages: 45-57
ISSN: 1354-3784 (ISSN-L)
1744-7658
DOI: 10.1517/13543784.2012.638282
OpenAlex: W2038245016
Cited by: 69
References: 80
Citations by year: 2026: 3 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 8 · 2016: 5 · 2015: 5 · 2014: 11 · 2013: 12 · 2012: 6
FWCI: 1.29
Type: journal article
Language: en
Open access: closed
Locations: Expert Opinion on Investigational Drugs (publishedVersion)
PubMed (publishedVersion)
Funders: Novo Nordisk
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, lixisenatide, albiglutide, glycemic control, weight loss, glucose homeostasis, mechanism of action, drug development, tolerability
MeSH terms: Glucagon-Like Peptide-1 Receptor, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Homeostasis, Humans, Hypoglycemic Agents, Drug Approval, Receptors, Glucagon

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Novel GLP-1 receptor agonists for diabetes

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks